Despite these challenges, subsequent anti-CGRP monoclonal antibodies like erenumab, fremanezumab, and galcanezumab have demonstrated better safety and efficacy, while gepants, including rimegepant and atogepant, have also been approved for migraine prevention. This evidence concerns the gene CALCA and migraine disorder.